Article
FDA perspectives on potential microarray-based clinical diagnostics.
Human genomics - 1 Jan 2006
Tezak Zivana, Ranamukhaarachchi Daya, Russek-Cohen Estelle, Gutman Steven I
Abstract excerpt
The US Food and Drug Administration (FDA) encourages the development of new technologies such as microarrays which may improve and streamline assessments of safety and the effectiveness of medical products for the benefit of public health. The FDA anticipates that these new technologies may offer the potential for more effective approaches to medical treatment and disease prevention and management. This paper...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.